Patents by Inventor Junjian Liu
Junjian Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312741Abstract: The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to CD73 and compositions comprising the antibodies or antigen-binding fragments thereof. The present invention also relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention, a vector comprising the polynucleotide, a host cell comprising the nucleic acid or the vector, an immunoconjugate and pharmaceutical composition comprising the antibody or antigen-binding fragment thereof. Furthermore, the present invention relates to the uses of these antibodies or antigen-binding fragments thereof in the immunotherapy, prevention and/or diagnosis of diseases.Type: ApplicationFiled: June 21, 2021Publication date: October 5, 2023Inventors: Hua JING, Haoran SHEN, Rong TANG, Junjian LIU
-
Patent number: 11746148Abstract: The present invention provides an artificially designed antibody molecule comprising four polypeptide chains, where each of the first polypeptide chain and the third polypeptide chain comprises an immunoglobulin light chain, and each of the second polypeptide chain and the fourth polypeptide chain comprises, from the N-terminus to the C-terminus, an immunoglobulin heavy chain variable region, an immunoglobulin CH1 domain, a VHH, an immunoglobulin CH2 domain, an immunoglobulin CH3 domain, and optionally an immunoglobulin CH4 domain. The present invention also provides a polynucleotide encoding the antibody molecule, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, an immunoconjugate and a pharmaceutical composition comprising the antibody molecule, and use of the antibody molecule in the immunotherapy, prevention and/or diagnosis of diseases.Type: GrantFiled: March 26, 2019Date of Patent: September 5, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Junjian Liu, Xiaoniu Miao, Zhihui Kuang
-
Patent number: 11732044Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.Type: GrantFiled: December 27, 2018Date of Patent: August 22, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoniu Miao, Huajing Hu, Andy Tsun, Junjian Liu, Xiaolin Liu
-
Patent number: 11708417Abstract: An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.Type: GrantFiled: March 26, 2019Date of Patent: July 25, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTDInventors: Xiaoniu Miao, Zhihui Kuang, Weifeng Huang, Junjian Liu
-
Publication number: 20230174604Abstract: The present invention relates to a novel interleukin-2 (IL-2) mutant protein. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.Type: ApplicationFiled: March 19, 2021Publication date: June 8, 2023Inventors: Fenggen FU, Shuaixiang ZHOU, Weiwei WU, Kaijie HE, Junjian LIU
-
Patent number: 11655296Abstract: The present invention relates to novel antibodies and antibody fragments thereof that specifically bind to integrin-associated proteins (IAP, or CD47), and a composition comprising the antibodies or the antibody fragments. The present invention also relates to a nucleic acid encoding the antibodies or the antibody fragments thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention also relates to therapeutic and diagnostic use of the antibodies and the antibody fragments.Type: GrantFiled: March 26, 2019Date of Patent: May 23, 2023Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Dandan Liu, Weifeng Huang, Bingliang Chen, Junjian Liu
-
Publication number: 20230090351Abstract: A key filling method includes transmitting first filling information to a server, the first filling information indicates to a security chip a filling permission of an electronic device; obtaining second filling information that includes a verification public key generated by the server. In accordance with a determination that the electronic device has the filling permission based on the first filling information, the second filling information comprises filling information transmitted by the server to the electronic device; and filling the verification public key into the security chip, the verification public key being used for encrypting information, and a verification private key corresponding to the verification public key being used for decrypting the encrypted information.Type: ApplicationFiled: November 15, 2022Publication date: March 23, 2023Inventors: Junjian LIU, WEIMING YANG, DONGQING HUANG, RUNZENG GUO
-
Patent number: 11512131Abstract: The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.Type: GrantFiled: December 27, 2018Date of Patent: November 29, 2022Assignee: Innovent Biologies (Suzhou) Co., Ltd.Inventors: Xiaoniu Miao, Huajing Hu, Junjian Liu, Bingliang Chen, Li Li
-
Patent number: 11498972Abstract: The present invention relates to an antibody and antibody fragment that specifically binds to OX40 and to a composition comprising said antibody or antibody fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or antibody fragment thereof and a host cell comprising the same, and to a related use thereof. In addition, the present invention relates to the use of the antibody and antibody fragment for treatment and diagnosis.Type: GrantFiled: March 23, 2018Date of Patent: November 15, 2022Assignee: Innovent Biologics (Suzhou) Co., Ltd.Inventors: Andy Tsun, Hemanta Baruah, Xiaolin Liu, Cheng Chen, Junjian Liu, Bingliang Chen, Weifeng Huang
-
Publication number: 20220267458Abstract: An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.Type: ApplicationFiled: March 26, 2019Publication date: August 25, 2022Inventors: Xiaoniu MIAO, Zhihui KUANG, Weifeng HUANG, Junjian LIU
-
Publication number: 20220227870Abstract: The present invention provides a novel artificial triple-chain antibody comprising three polypeptide chains, wherein a first polypeptide chain comprises a first heavy-chain variable domain, a second polypeptide chain comprises a first light-chain variable domain that is paired with the first heavy-chain variable domain to form a first antigen-binding site; and a third polypeptide chain comprises a second single-domain antigen-binding site and a third single-domain antigen-binding site. The present invention also provides a polynucleotide encoding the triple-chain antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or vector, an immunoconjugate comprising the triple-chain antibody and a pharmaceutical composition comprising the triple-chain antibody or the immunoconjugate thereof, and use of the triple-chain antibody in immunotherapy, prevention and/or diagnosis of diseases.Type: ApplicationFiled: December 26, 2018Publication date: July 21, 2022Applicant: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xiaoniu MIAO, Zhihui KUANG, Huajing HU, Haiqing NI, Junjian LIU
-
Publication number: 20220207036Abstract: A data operation method includes: parsing, in response to receiving a data read request, the data read request to obtain a query condition; querying data satisfying the query condition in a not only structured query language (NoSQL) database (DB) when the query condition satisfies a preset high-frequency access condition; querying data satisfying the query condition in a relational DB when the query condition satisfies a preset complex access condition, data stored in the NoSQL DB and the relational DB being consistent; responding to the data read request based on the queried data.Type: ApplicationFiled: March 16, 2022Publication date: June 30, 2022Inventors: Xiao OU, Dongqing HUANG, Junjian LIU, Jiandong LI
-
Patent number: 11370837Abstract: The present invention relates to a novel antibody and an antibody fragment thereof that specifically bind to TIGIT and a composition comprising the antibody or the antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the present invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment.Type: GrantFiled: July 25, 2019Date of Patent: June 28, 2022Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Xinzhen Shi, Pan Zhang, Junjian Liu
-
Publication number: 20220127364Abstract: The present invention relates to a novel single-domain antibody and a fragment thereof that specifically bind to PD-L1 and a composition comprising the antibody or the fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or the fragment thereof, a host cell comprising the nucleic acid, and related uses. Furthermore, the present invention relates to therapeutic and diagnostic uses of the antibody and the fragment thereof. In particular, the present invention relates to combination therapies of these antibodies and the fragments thereof with other therapies, such as therapeutic modalities or therapeutic agents.Type: ApplicationFiled: January 31, 2020Publication date: April 28, 2022Inventors: Chunyin GU, Qian ZHOU, Zhihui KUANG, Junjian LIU
-
NOVEL BISPECIFIC ANTIBODY MOLECULE AND BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO PD-L1 AND LAG-3
Publication number: 20220112284Abstract: The present invention provides a novel, artificially designed antibody molecule comprising: a polypeptide chain of formula (I): VH-CH1-Fc-X-VHH; and a polypeptide chain of formula (II): VL-CL; wherein: the VH represents a heavy chain variable region; the CH represents a heavy chain constant region; the Fc comprises CH2, CH3, and optionally CH4; the CH1, the CH2, the CH3 and the CH4 represent domains 1, 2, 3 and 4, respectively, of the heavy chain constant region; the X may be absent, or represents a linker such as a flexible linker when present; the VHH represents a single-domain antigen-binding site such as a single-domain antibody; the VL represents a light chain variable region; the CL represents a light chain constant region; optionally, a hinge region is present between the CH1 and the Fc.Type: ApplicationFiled: January 23, 2020Publication date: April 14, 2022Inventors: Haiqing NI, Bingliang CHEN, Junjian LIU -
Patent number: 11292836Abstract: The present invention is directed to a novel antibody against CD47 and the antibody fragments thereof and a composition comprising the antibody or antibody fragments thereof. The present invention relates further to a nucleic acid encoding the antibodies or antibody fragments thereof and host cells comprise the same, as well as the relevant use of the same. In addition, the present invention is also directed to the use of these antibodies and antibody fragments in the therapy and diagnosis.Type: GrantFiled: August 28, 2018Date of Patent: April 5, 2022Assignee: INNOVENT BIOLOGICS (SUZHOU) CO., LTD.Inventors: Andy Tsun, Dandan Liu, Bingliang Chen, Junjian Liu
-
Patent number: 11266690Abstract: The invention provides a chimeric antigen receptor (CAR) which can specifically bind to a BCMA protein comprising a BCMA binding structural domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. The invention also provides uses of the CAR in treating diseases or conditions linked to the expression of BCMA.Type: GrantFiled: January 31, 2019Date of Patent: March 8, 2022Assignees: Nanjing IASO Biotherapeutics Co., Ltd., Innovent Biologics (Suzhou) Co., Ltd.Inventors: Jianfeng Zhou, Junjian Liu, Guang Hu, Yongkun Yang, Guangrong Meng, Wenjing Gao, Yuyu Wang, Panpan Niu
-
Publication number: 20220041702Abstract: The present invention provides a novel, artificially designed antibody molecule comprising: (i) single-domain antigen-binding sites; (ii) antigen-binding Fab fragments; wherein the single-domain antigen-binding site is located at the N-terminus of a light chain variable domain (VL) of the antigen-binding Fab fragment or the C-terminus of a light chain constant region (CL) of the antigen-binding Fab fragment or the single-domain antigen-binding site is located at the N-terminus of a heavy chain variable domain (VH) or the C-terminus of an immunoglobulin CH1 domain of the antigen-binding Fab fragment, the single-domain antigen-binding site and the antigen-binding Fab fragment bind to the same antigen or different antigens, and the single-domain antigen-binding site and the antigen-binding Fab fragment have or do not have a linker peptide therebetween; and (iii) immunoglobulin Fc domains located at the C-terminus of the single-domain antigen-binding site or the antigen-binding Fab fragment.Type: ApplicationFiled: March 26, 2019Publication date: February 10, 2022Inventors: Junjian LIU, Xiaoniu MIAO, Zhihui KUANG
-
Publication number: 20210371529Abstract: The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.Type: ApplicationFiled: December 27, 2018Publication date: December 2, 2021Inventors: Xiaoniu MIAO, Huajing HU, Andy TSUN, Junjian LIU, Xiaolin LIU
-
Publication number: 20210221863Abstract: The present invention relates to a novel interleukin-2 (IL-2) mutant protein and use thereof. In particular, the present invention relates to an IL-2 mutant protein with reduced IL-2R? receptor binding ability and/or increased IL-2R? receptor binding ability compared with the wild-type IL-2. The present invention further provides a fusion protein and an immunoconjugate comprising the IL-2 mutant protein, a nucleic acid encoding the IL-2 mutant protein, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-2 mutant protein, a pharmaceutical composition comprising the IL-2 mutant protein, and therapeutic use of the mutant protein.Type: ApplicationFiled: September 20, 2019Publication date: July 22, 2021Inventors: Lishan KANG, Chunyin GU, Fenggen FU, Shuaixiang ZHOU, Xinzhen SHI, Junjian LIU